Martin Leach
Director de Operaciones en Alloy Therapeutics LLC .
Perfil
Martin D.
Leach is currently the Chief Operating Officer at Alloy Therapeutics LLC since 2023.
Prior to this, he worked as the Vice President-Information at CuraGen Corp.
Dr. Leach holds a graduate degree from MIT Sloan School of Management and a doctorate degree from Boston University School of Medicine.
Cargos activos de Martin Leach
Empresas | Cargo | Inicio |
---|---|---|
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Director de Operaciones | 29/06/2023 |
Antiguos cargos conocidos de Martin Leach.
Empresas | Cargo | Fin |
---|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Director Técnico/Científico/I+D | - |
Formación de Martin Leach.
Boston University School of Medicine | Doctorate Degree |
MIT Sloan School of Management | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Alloy Therapeutics LLC
Alloy Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Alloy Therapeutics LLC is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and company creation capabilities for discovering and developing therapeutic biologics. The company's lead offering is the ATX-GX™ platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Through a community of partners across academia, biotech, and the largest biopharma, Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Hanover, NH, with European labs in Switzerland. The company was founded by Errik B. Anderson, who has been the CEO since incorporation. | Commercial Services |
- Bolsa de valores
- Insiders
- Martin Leach